Company intelligence / Profile preview

Douglas E. Feltner

Ownership: Private
Development stage: Phase 1

Overview

Exicure, Inc. was a biotechnology company focused on developing spherical nucleic acid (SNA™) constructs for gene regulation and immunotherapy. The company ceased operations after failing to secure additional funding. They were acquired by Ocean Ridge Bio.

Therapeutic areas: Neurology
Modalities: Spherical nucleic acids (SNA™) constructs for gene regulation/immunotherapyGene therapies
Industry: Biotech

Drug pipeline

2 assets

AST-008

Phase 1

Indications: Advanced solid tumors

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Douglas E. Feltner.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Douglas E. Feltner.

Explore the full profile